DNA X Amends 8-K: $5.6M Series B Preferred Financing Lifts Pro Forma Equity Above Nasdaq Minimum
SONM sits 60% above its 52-week low of $2.521.
Summary
DNA X amended its July 2 financing disclosure, revealing it issued 929,864 Series B preferred shares for $5.6 million in total consideration and now believes it meets Nasdaq's equity listing rule with $3.8 million in pro forma stockholders' equity.
Key Events · Financing and Capital Events · SONM
-
Series B Preferred Financing Details
Issued 929,864 shares of Series B Preferred Stock for $2.5 million cash and cancellation of $3.1 million in convertible debt, totaling $5.6 million in consideration.
-
Remaining Shares to Be Issued
An additional 416,667 shares are expected to be sold by August 14, 2026, under the purchase agreement.
-
Nasdaq Compliance Update
Pro forma stockholders' equity estimated at $3.8 million as of July 9, 2026, exceeding the $2.5 million Nasdaq minimum; company awaits formal determination.
-
Certificate of Designation Filed
Filed with Delaware on July 6, 2026, establishing the rights and preferences of the Series B Preferred Stock.
Analysis · SONM · Manufacturing
The specific terms of DNA X's Series B Preferred Stock financing have now been disclosed: 929,864 shares were issued for $2.5 million in cash and $3.1 million in debt cancellation. Another 416,667 shares are expected by August 14. Crucially, the company estimates pro forma stockholders' equity of $3.8 million, which exceeds Nasdaq's $2.5 million continued listing threshold—a direct response to the May 27 delisting notice. This amendment transforms the original 8-K's vague announcement into a concrete path to regaining compliance, though the equity boost hinges on the full closing of the deal.
At the time of this filing, SONM was trading at $4.03 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $6M. The 52-week trading range was $2.52 to $16.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.